FINWIRES · TerminalLIVE
FINWIRES

Research Alert: Eastman Chemical Posts Mixed Q1 Results

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

Eastman Chemical posted Q1 adjusted EPS of $1.09, down from $1.91 a year ago, missing our $1.37 estimate but beating the $1.06 consensus. Sales fell 5% to $2.177B amid customer inventory destocking, weak consumer discretionary demand, and Middle East conflict impacts. The company implemented ~$500M in price increases to offset raw material inflation, while the Kingsport methanolysis facility remained on track to deliver ~$30M in incremental full-year earnings. Management maintained its cost-reduction target of $125M-$150M in savings net of inflation for 2026. Adjusted EBIT margin contracted 440 bps to 9.2% as lower volumes and challenging market conditions compressed profitability across most segments, though sequential improvement emerged with specialty business volume/mix rising over 10% and EBIT margins expanding 240 bps from Q4. The company maintained financial flexibility with $665M in cash and a solid investment-grade balance sheet.

Related Articles

Research

Research Alert: CFRA Lowers Opinion On Adss Of Deutsche Bank To Sell From Hold

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our rating to Sell (from Hold) and cut our 12-month target price to USD28 (from USD37). This is based on applying a reduced target P/E multiple of 7.1x (from 9.1x) to our unchanged 2026 EPS forecast. The multiple contraction reflects the invalidation of our previous thesis that the bank had moved beyond its historical risk profile following its Q1 2026 results. A sharp increase in credit provisions challenges the de-risking narrative, a decline in the CET1 capital ratio weakens the capital return story, and faltering performance in core divisions confirms the bank's vulnerability to a deteriorating macroeconomic backdrop. The market's negative reaction underscores a loss of confidence in the quality of the bank's earnings and its ability to navigate mounting headwinds. The risk-reward profile, which we previously saw as balanced, is now clearly skewed to the negative.

$DB
Research

Research Alert: CFRA Keeps Hold Rating On Shares Of Automatic Data Processing, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target price by $50 to $235, valuing shares at 20.1x our next-12-month EPS estimate, a discount to ADP's five-year average forward P/E of 28.5x. We increase our FY 26 EPS estimate by $0.06 to $11.05 and keep FY 27's at $11.94 on respective revenue forecasts of $21.87B (+6%) and $23.03B (+5%). Management's raised guidance across multiple metrics reflects growing confidence in the business model's resilience and the client funds strategy's trajectory. The company increased full-year FY 26 revenue growth expectations to 6%-7% (from approximately 6%) and adjusted diluted EPS growth to 10%-11% (from 9%-10%). Additionally, management raised adjusted EBIT margin expansion guidance to 70 bps-80 bps (from 50 bps-70 bps) and improved U.S. pays per control expectations to approximately 1% (from flat), suggesting continued cautious optimism about employment trends while maintaining focus on the client funds investment strategy as the primary value driver.

$ADP
Research

Research Alert: CFRA Keeps Hold Opinion On Shares Of Mondelez International

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price of $63, raised $1, reflects a 19x multiple of projected 2027 EPS, in line with MDLZ's historical forward P/E average. We raise our 2026 EPS estimate by $0.06 to $3.08, but cut 2027's by $0.11 to $3.32. We continue to see headwinds related to chocolate and biscuits divisions, though favorable forex has been helping to a degree. MDLZ highlighted plans to stimulate growth with more promotional activity, which could boost revenues (we see an acceleration in revenues in 2027), but may come with the trade-off of narrower margins. We note that cost-saving efforts can also contribute to staving off some of the margin pressure. MDLZ is largely hedged on its cocoa input costs for 2026 but less so in 2027. Thus, if the substantial rise in cocoa pricing in 2025 does not reemerge, it should help the bottom line in 2027 as cost pressures should ease. Share buybacks have also contributed to EPS, and we note that Q1 2026 share count was down 1.5% from one year earlier.

$MDLZ